Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
| ▸ | TOP2A | P11388 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11407529 | 0.90 | DGKA (0.47) | DGKAMGLLADRA2AADRA1ADNM1 | |
| SCHEMBL2397923 | 0.89 | DGKA (0.48) | DGKAMGLLDNM1MAPTHTR2C | |
| SCHEMBL2397583 | 0.84 | CYP1A2 (0.45) | ALDH1A1L3MBTL1 | |
| SCHEMBL16047225 | 0.81 | DGKA (0.40) | DGKAMGLLADRA2AADRA1ADNM1 | |
| SCHEMBL11407646 | 0.78 | DGKA (0.53) | DGKAMGLLDNM1MAPTHTR2C | |
| SCHEMBL6363267 | 0.77 | MGLL (0.51) | DGKAMGLLADRA2AADRA1ADNM1 | |
| SCHEMBL20589 | 0.76 | DGKA (0.58) | DGKAADRA2AADRA1ADNM1MAPT | |
| SCHEMBL11410912 | 0.76 | NAAA (0.60) | DGKAMGLLDNM1HTR2CNAAA | |
| SCHEMBL11411227 | 0.76 | NAAA (0.60) | DGKAMGLLDNM1HTR2CNAAA | |
| SCHEMBL11407523 | 0.76 | NAAA (0.60) | DGKAMGLLDNM1HTR2CNAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8017797-B2 | Method for producing phosphorus-containing α-keto acid | MEIJI SEIKA KAISHA LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20100063313-A1 | METHOD FOR PRODUCING PHOSPHORUS-CONTAINING ALPHA-KETO ACID | MEIJI SEIKA KAISHA LTD., (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2133356-A1 | PROCESS FOR PRODUCTION OF PHOSPHORUS-CONTAINING -KETO ACID | Meiji Seika Kaisha, Ltd. (JP) | 2009-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063313-A1 | METHOD FOR PRODUCING PHOSPHORUS-CONTAINING ALPHA-KETO ACID | PRKAB1, PRKAB2, PLCB1 | DGKA 494/4885MGLL 759/4885ADRA2A 1651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.